Assessment of the Influence of Inflammation and FCGR3A Genotype on Infliximab Pharmacokinetics and Time to Relapse in Patients with Crohn’s Disease - Archive ouverte HAL Access content directly
Journal Articles Clinical Pharmacokinetics Year : 2015

Assessment of the Influence of Inflammation and FCGR3A Genotype on Infliximab Pharmacokinetics and Time to Relapse in Patients with Crohn’s Disease

(1) , (2) , (3) , (1) , (4) , (5) , (6) , (1)
1
2
3
4
5
6

Abstract

Infliximab is a monoclonal anti-tumor necrosis factor-α (anti-TNFα) antibody that profoundly modified the treatment of Crohn's disease (CD). The polymorphism of Fc fragment of IgG, low affinity IIIa, receptor (CD16a) [FCGR3A] influences the biological response to infliximab in patients with CD. Our aim was to study its influence on infliximab pharmacokinetics and risk of relapse after infliximab discontinuation.
Not file

Dates and versions

hal-02425490 , version 1 (30-12-2019)

Identifiers

Cite

David Ternant, Zahir Berkane, Laurence Picon, Valérie Gouilleux-Gruart, Jean-Frédéric Colombel, et al.. Assessment of the Influence of Inflammation and FCGR3A Genotype on Infliximab Pharmacokinetics and Time to Relapse in Patients with Crohn’s Disease. Clinical Pharmacokinetics, 2015, 54 (5), pp.551-562. ⟨10.1007/s40262-014-0225-3⟩. ⟨hal-02425490⟩
32 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More